Immunostimulatory CpG SD-101 + RT in Recurrent/Progressive Lymphoma After Allogeneic Hematopoietic Cell Transplantation (HCT)

Phase 1TerminatedNCT01745354

Robert Lowsky6 enrolled

Overview

For patients with lymphoma that recurs after chemotherapy, bone marrow transplantation using cells from a healthy donor represents potentially curative treatment. In these individuals, cure is possible because transplantation of healthy donor immune cells can fight the lymphoma in the patient. The goal of this work is to test a strategy that activates the healthy donor immune cells so that they more effectively fight lymphoma and can result in an increased cure rate for these patients. Our group has previously studied CpG, an immune activating medication, in patients with lymphoma and demonstrated modest anti-tumor responses. We now have a more potent form of CpG which we intend to test to see if it will better activate the donor immune cells and result in shrinkage of tumor throughout the entire body, not just at the injected site.

Patients will receive low dose radiation to all bulky or symptomatic lymph nodes on days -2 and -1. SD-101 will be administered intratumorally to the single largest palpable node within 24 hours after completion of radiation, on day 0. Two additional intratumoral SD-101 injections will be performed on days 7 (+/- 2 days) and 14 (+/- 2 days). This is a dose ranging study using a 3+3 design with a definition of maximum tolerated dose (MTD) which our group has found acceptable in the past. The first cohort of patients will receive a SD-101 dose of 0.3 mg per injection. The dose will be escalated to 1 mg and 3 mg based on dose limiting toxicity (DLT).

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Lymphoma, Non-Hodgkin

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Biopsy-confirmed relapsed, refractory, or progressive NHL or HL (Refer to Section 3.2.1 for excluded subtypes) * At least 3 sites of disease 1. One for diagnosis (lymph node or bone marrow biopsy) 2. One palpable for treatment 3. One measurable radiographically * \> 60 days after RIC allogeneic transplant for lymphoma * 18 years of age or older * Mixed (5-95%) or complete (\>95%) chimerism * Eastern Oncology Cooperative Group (ECOG) performance status ≤ 2 * ANC \>1000/mm3, platelets \>50,000/mm3 * Total bilirubin ≤ 2.5 mg/dL, AST and ALT \< 3 times upper limit of normal * Serum creatinine ≤ 3 mg/dL * No chemotherapy, RT, DLI or biologic therapy for lymphoma at least 4 weeks prior to scheduled treatment * Minimal immunosuppression (defined as monotherapy with ≤ 10 mg prednisone daily, ≤ 200 mg cyclosporine daily, or ≤ 2 mg tacrolimus daily) at least 2 weeks prior to scheduled treatment Exclusion Criteria: * HIV associated lymphoma * Acute GVHD at time of enrollment (history of treated and resolved GVHD is permitted) * Active infection within 14 days prior to scheduled treatment * Active Cytomegalovirus (CMV) disease at the time of enrollment * Pre-existing autoimmune or antibody mediated disease (including systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjogren's syndrome, and autoimmune thrombocytopenia) * Pregnant

Outcomes

Primary Outcomes

Determination of the maximum tolerated dose based on dose limiting toxicity defined as any new grade 3-4 toxicity after the first SD-101 administration

Time frame: 60 Days

Secondary Outcomes

Measure cytotoxic T-cell activity changes pre- and post-treatment of tumor infiltrating lymphocytes and peripheral blood lymphocytes using ELISA and Immunohistochemistry.

Time frame: 2, 3, 8 weeks after treatment

Measure tumor response by PET-CT scan imaging

Time frame: 8 weeks after treatment

Measure level of donor specific tumor infiltrating lymphocytes by flow cytometry and Immunofluorescence

Collect PBMCs